TRU-015 for the Treatment of Rheumatoid Arthritis. According to Datamonitor, rheumatoid arthritis, or RA, is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. Total reported worldwide sales of protein therapeutics used for the treatment of RA were $7.6 billion in 2005 and are expected to grow to $10 billion in 2010

EX-10.23 13 v18917a3exv10w23.txt EXHIBIT 10.23 EXHIBIT 10.23 AMENDMENT No. 10 to THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT Dated 08 January 2004 Between LONZA BIOLOGICS PLC and TRUBION PHARMACEUTICALS, INC. CONFIDENTIAL TREATMENT THIS AMENDMENT No. 10 ("Tenth Amendment") is made the 20th day of December 2005 BETWEEN LONZA BIOLOGICS PLC of 228 Bath Road, Slough, Berkshire SL1 4DX, England (hereinafter referred to as "LB"), and TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA 98121, USA (herein after referred to as the "Customer") WHEREAS A. LB and the Customer entered into a development and manufacturing services agreement ("the Agreement") dated 08 January 2004, pursuant to which LB agreed to provide Services to the Customer, and, B. The Customer now wishes LB to perform additional services under the Agreement, and, C. LB is willing to perform such additional services on the terms set out in the Agreement, and D. The parties wish to amend the Agreement in accordance with Clause 13.5 thereto. NOW THEREFORE IT IS HEREBY AGREED as follows: 1.0 Two new Stages, Stage 32 and Stage 33, shall be added to Schedule 2 of the Agreement to read as follows: CONFIDENTIAL TREATMENT 32. "Stage 32 - *** 32.1 Objective *** 32.2 Activities *** 32.3 Timescale This Stage may commence upon issue of the protocol. This Stage shall be complete with the issue of the report of activities. It is estimated that this report shall be issued *** from commencement of this Stage. 33. Stage 33 - *** 33.1 Objectives *** 33.2 Activities *** 33.3 Timescale This Stage may commence as soon as Product is available and shall be complete on issue of the final report of activities (Activity 33.2.4) and it is estimated that this will be issued *** from the preparation of the protocol. From issue of the protocol it is estimated that the elapsed time until the Customer review of the report is ***. Note: The Customer shall review the draft protocol and the audited report (activity 33.2.1 and 33.2.4) within *** of receiving the document from LB. If the Customer's comments are not returned to LB within this time Lonza reserves the right to issue the protocol or final study report" CONFIDENTIAL TREATMENT -2- SCHEDULE 3 TO THE AGREEMENT SHALL BE AMENDED TO INCLUDE PROVISION FOR PAYMENT FOR THE ABOVE MENTIONED ADDITIONAL SERVICES, AS SET OUT BELOW HERETO. INVOICES FOR THESE ADDITIONAL SERVICES SHALL BE ISSUED, AND CUSTOMER PAYMENTS SHALL BE MADE, IN *** "1. PRICE *** 2. PAYMENT FOR STAGE 32 *** upon commencement of Stage 32. *** upon completion of Stage 32. Testing Laboratory charges will be invoiced separately. FOR STAGE 33 *** upon commencement of Stage 33. *** upon completion of Stage 33 Testing Laboratory charges will be invoiced separately" CONFIDENTIAL TREATMENT -3- SAVE AS HEREIN PROVIDED ALL OTHER TERMS AND CONDITIONS OF THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT. AS WITNESS the hands of the duly authorised representatives of the parties hereto the day and year first above written. Signed for and on behalf of LONZA BIOLOGICS PLC /s/ Ian Elvins ---------------------------------------- VP Global Biologics Quality TITLE Signed for and on behalf of TRUBION PHARMACEUTICALS, INC /s/ Kendall M. Mohler ---------------------------------------- Senior VP, Research & Development TITLE CONFIDENTIAL TREATMENT -4-